Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Duncan R Hewett

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Experimental Hematology|June 16, 2025
Mer receptor expression promotes multiple myeloma disease development via a cell-extrinsic mechanismJustine R Clark, Vasilios Panagopoulos, Jacqueline E Noll, et al.
The Journal of Experimental Medicine|April 12, 2006
Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsionPadraic G Fallon, Sarah J Ballantyne, Niamh E Mangan, et al.
Haematologica|April 2, 2026
Therapeutic inhibition of myeloperoxidase with AZD5904 attenuates disease progression in mouse models of early-stage and relapsed multiple myelomaConnor M D Williams, Jacqueline E Noll, Dylan Harnas, et al.
Cancer Letters|February 5, 2020
Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myelomaChee Man Cheong, Krzysztof M Mrozik, Duncan R Hewett, et al.
Experimental Cell Research|February 1, 2015
Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivoChee Man Cheong, Annie W S Chow, Stephen Fitter, et al.
Leukemia Research|March 13, 2024
Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell linesMara N Zeissig, Duncan R Hewett, Krzysztof M Mrozik, et al.
FASEB Bioadvances|July 4, 2020
LCRF-0006, a small molecule mimetic of the N-cadherin antagonist peptide ADH-1, synergistically increases multiple myeloma response to bortezomibKrzysztof M Mrozik, Chee M Cheong, Duncan R Hewett, et al.
Oncotarget|May 4, 2017
Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stressCraig T Wallington-Beddoe, Melissa K Bennett, Kate Vandyke, et al.
Neoplasia (New York, N.Y.)|June 28, 2019
Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In VivoKhatora S Opperman, Kate Vandyke, Kimberley C Clark, et al.
Cancers|August 7, 2020
Targeted Disruption of Bone Marrow Stromal Cell-Derived Gremlin1 Limits Multiple Myeloma Disease Progression In VivoKimberley C Clark, Duncan R Hewett, Vasilios Panagopoulos, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Experimental Hematology|June 16, 2025
Mer receptor expression promotes multiple myeloma disease development via a cell-extrinsic mechanismJustine R Clark, Vasilios Panagopoulos, Jacqueline E Noll, et al.
The Journal of Experimental Medicine|April 12, 2006
Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsionPadraic G Fallon, Sarah J Ballantyne, Niamh E Mangan, et al.
Haematologica|April 2, 2026
Therapeutic inhibition of myeloperoxidase with AZD5904 attenuates disease progression in mouse models of early-stage and relapsed multiple myelomaConnor M D Williams, Jacqueline E Noll, Dylan Harnas, et al.
Cancer Letters|February 5, 2020
Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myelomaChee Man Cheong, Krzysztof M Mrozik, Duncan R Hewett, et al.
Experimental Cell Research|February 1, 2015
Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivoChee Man Cheong, Annie W S Chow, Stephen Fitter, et al.
Leukemia Research|March 13, 2024
Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell linesMara N Zeissig, Duncan R Hewett, Krzysztof M Mrozik, et al.
FASEB Bioadvances|July 4, 2020
LCRF-0006, a small molecule mimetic of the N-cadherin antagonist peptide ADH-1, synergistically increases multiple myeloma response to bortezomibKrzysztof M Mrozik, Chee M Cheong, Duncan R Hewett, et al.
Oncotarget|May 4, 2017
Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stressCraig T Wallington-Beddoe, Melissa K Bennett, Kate Vandyke, et al.
Neoplasia (New York, N.Y.)|June 28, 2019
Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In VivoKhatora S Opperman, Kate Vandyke, Kimberley C Clark, et al.
Cancers|August 7, 2020
Targeted Disruption of Bone Marrow Stromal Cell-Derived Gremlin1 Limits Multiple Myeloma Disease Progression In VivoKimberley C Clark, Duncan R Hewett, Vasilios Panagopoulos, et al.
Pageof 3